Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies

被引:21
|
作者
Wang, Meizhu [1 ,2 ]
Chen, Wenming [3 ]
Chen, Jiansheng [4 ]
Yuan, Sisi [1 ]
Hu, Jiliang [1 ]
Han, Bangxing [5 ,6 ]
Huang, Yahui [4 ]
Zhou, Wen [2 ]
机构
[1] Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, E-232,Waihuan Rd, Guangzhou 510006, Peoples R China
[2] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Shanghai 200241, Peoples R China
[3] Hunan Univ Chinese Med, Dept Pharmaceut Prod Ctr, Hosp 1, 95 Shaoshan Rd, Changsha 41007, Hunan, Peoples R China
[4] South China Agr Univ, Coll Hort, 43 Wushan Rd, Guangzhou 510642, Guangdong, Peoples R China
[5] West Anhui Univ, Dept Biol & Pharmaceut Engn, Luan, Anhui, Peoples R China
[6] West Anhui Univ, Anhui Engn Lab Conservat & Sustainable Utilizat T, Luan, Anhui, Peoples R China
基金
中国国家自然科学基金;
关键词
Cancer chemotherapy; Saccharide abnormality; Multi-drug resistance (MDR); Reversal strategy; POTENT ANTITUMOR-ACTIVITY; OVERCOME DRUG-RESISTANCE; ACUTE MYELOID-LEUKEMIA; PROSTATE-CANCER; INSULIN-RESISTANCE; HEPATOCELLULAR-CARCINOMA; GLUCOSE-METABOLISM; INDUCED APOPTOSIS; N-GLYCAN; IN-VITRO;
D O I
10.1016/j.ejmech.2021.113487
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Clinically, chemotherapy is the mainstay in the treatment of multiple cancers. However, highly adaptable and activated survival signaling pathways of cancer cells readily emerge after long exposure to chemotherapeutics drugs, resulting in multi-drug resistance (MDR) and treatment failure. Recently, growing evidences indicate that the molecular action mechanisms of cancer MDR are closely associated with abnormalities in saccharides. In this review, saccharides affecting cancer MDR development are elaborated and analyzed in terms of aberrant aerobic glycolysis and its related enzymes, abnormal glycan structures and their associated enzymes, and glycoproteins. The reversal strategies including depletion of ATP, circumventing the original MDR pathway, activation by or inhibition of sugar-related enzymes, combination therapy with traditional cytotoxic agents, and direct modification on the sugar moiety, are ultimately proposed. It follows that abnormal saccharides have a significant effect on cancer MDR development, providing a new perspective for overcoming MDR and improving the outcome of chemotherapy. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Strategies and validation for siRNA-based therapeutics for the reversal of multi-drug resistance in cancer
    Fatemian, Tahereh
    Othman, Iekhsan
    Chowdhury, Ezharul Hoque
    DRUG DISCOVERY TODAY, 2014, 19 (01) : 71 - 78
  • [2] Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro
    Pan, Guang-Dong
    Yang, Jian-Qing
    Yan, Lv-Nan
    Chu, Guang-Ping
    Liu, Qiang
    Xiao, Yi
    Yuan, Lin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (04) : 431 - 440
  • [4] Reversal of Multi-Drug Resistance by Vector-Based-ShRNA-Mdr1 In Vitro and In Vivo
    Lu, Shi
    Huang, Qi
    Wang, Zehua
    Song, Yinfeng
    Wang, Lijun
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2009, 29 (05) : 620 - 624
  • [5] Reversal of multi-drug resistance by vector-based-ShRNA-Mdr1 In Vitro and In Vivo
    Shi Lu
    Qi Huang
    Zehua Wang
    Yinfeng Song
    Lijun Wang
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29 : 620 - 624
  • [6] Reversal of Multi-Drug Resistance by Vector-Based-ShRNA-Mdr1 In Vitro and In Vivo
    卢实
    黄畦
    王泽华
    宋银峰
    王丽君
    Current Medical Science, 2009, 29 (05) : 620 - 624
  • [7] Formulation strategy to overcome multi-drug resistance (MDR)
    Cheong-Weon Cho
    Archives of Pharmacal Research, 2011, 34 : 511 - 513
  • [8] Formulation Strategy to Overcome Multi-Drug Resistance (MDR)
    Cho, Cheong-Weon
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (04) : 511 - 513
  • [9] Polyene multi-drug resistance reversal agents
    Andrus, MB
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (06) : 823 - 831
  • [10] Recent strategies for the treatment of multi-drug resistance in cancer cells
    Ojima, I
    Bounaud, PY
    Oderda, CF
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (12) : 1587 - 1598